Particles & Health 2021 20th & 21st October 2021

Particles & Health 2021

An international conference addressing issues in science and regulation

20th & 21st October 2021

Pullman London St Pancras

100 - 110 Euston Road, London, NW1 2AJ

Sponsored by IOM 

Visit the website: 




Regulatory initiatives in the European Union (EU) have resulted in proposed classifications for all poorly soluble low toxicity particles (PSLTs) for carcinogenicity. Examples of PSLTs include carbon black, titanium dioxide and iron oxide, among
others. Approaches have also been proposed for setting workplace exposure limits for these materials, such as by the German MAK Commission.

This scientific conference will facilitate interaction and discussions among attendees with expertise in toxicology, epidemiology, occupational and pulmonary medicine and exposure assessment. The purpose of this conference is to promote interactions between these different disciplines to aid in the sound and evidence-based scientific
underpinning of regulatory standard considerations regarding PSLTs. Although regulatory concern regarding PSLTs has focused on lung cancer risk as a result of rat inhalation overload studies, this conference will address all relevant health end points, including genetic and reproductive issues as well, consistent with ECHA guidelines.

Scientific Program Committee
Robert McCunney MD, MPH (Chair), Nathan Baker, Len Levy PhD, Kevin Driscoll PhD, Paul Borm PhD,

Nils Krueger DVM, Dominique Lison MD, PhD, Lang Tran PhD, Rodger Duffin PhD, Vicki Stone PhD



Sample of Topics related to substances that may be characterized as PSLTs, including carbon black, coal, titanium dioxide, cerium oxide, aluminum oxide barium sulfate and iron oxide, among others.

  • Defining PSLTs
  • Epidemiological studies of PSLTs
  • Inhalation studies evaluating human cellular response to particles
  • Basic research studies on inflammatory to malignancy pathways
  • Animal studies, PLSTs and human risk: “New Insights into old data.”
  • New studies on PSLTs; 2 year carcinogenicity assays; Role of the rodent model in human risk assessment of PSLTs and lung cancer risk
  • Animal studies and gender specific responses to PSLTs. How does the USA National Cancer Institute (NCI) and National Institute of Environmental Health Sciences (NIEHS) address this challenge of extrapolating rodent data to human risk assessment?
  • Adverse Outcome Pathways (AOPs) and Modes of Action (MOA): identification and recommendations for closing gaps in knowledge for rodents and humans.
  • Are there lessons to be learned from how the pharmaceutical industry’s approach to translational science (safety and efficacy) as evolved in recent years?
  • Setting exposure limits for PSLTs and Translational Toxicology.
  • Genotoxicity and Reproductive toxicity studies of PSLTs.
  • Nanoparticle inhalation – kinetics, bioprocessing and non-pulmonary responses.

Conference supported by a grant from the International Carbon Black Association